Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with cushing syndrome

February 2, 2023

Moritis et al • 2022 • European Congress of Endocrinology

When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis

January 30, 2023

Aresta et al • 2021 • Endocr Pract.

Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search

November 25, 2022

Isaac Sachmechi, MD, FACE, FACP; Sanna Salam; Muhammad Umair, MD; Kathleen Wade Tarnowski, MSc • 2021 •

GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

November 17, 2022

Auchus et al. • 2020 • J Endocr Soc. Vol 4, Issue Suppl 1 April-May

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

July 15, 2021

Pivonello et al • 2021 • Front. Endocrinol., 14 July 2021